Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
- Q1 2026 Federal Psychedelic Lobbying Update
- State of Maryland and Reason for Hope Fund Sunstone Study to Compare Group vs. Individual MDMA-Assisted Therapy for PTSD
- Australia Loosens Psychedelics Access Pathway Regulations
- VA Launches “New” MDMA Trial, First Announced in December 2024
- Other Stories
- New Poll Finds Brits Generally Supportive of Psilocybin Access
- Swedish Study Reports Antidepressant Effect of Psilocybin in MDD
- EPIsoDE Follow-Up Data Suggest Sustained Antidepressant Response to Psilocybin
- Other Headlines
- In Case You Missed It
It’s been an incredibly busy few weeks since our last Bulletin, with Psychedelic Alpha on the road in the U.S. (for APA’s annual meeting and a visit to Stanford and the valley), The Real Mental Health Summit in London, and now the Interdisciplinary Conference on Psychedelic Research in Haarlem, the Netherlands.
We have published a wealth of content since our last Bulletin, including our first audio dispatch. Do look out for the ‘In Case You Missed It’ segment at the bottom of this piece to ensure you’re making the most of your Pα+ subscription.
Q1 2026 Federal Psychedelic Lobbying Update
Now that federal lobbying data from the first quarter of the year is available to retrieve, we present our regular update on the state of activity across psychedelic ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks